Shipping giant UPS is putting more money behind the part of its business it is betting its future on. On Monday, June 22, United Parcel Service announced a $48 million investment to build 27 temperature-controlled freight cross-dock facilities around the world, a direct play for the booming trade in drugs that must be kept cold, including GLP-1 weight-loss injectables.

“Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world,” said Kate Gutmann, the company’s executive vice president and president of international, healthcare and supply chain solutions.

The new facilities, spread across the Americas, Europe and Asia, are built to hold shipments at strict temperature bands — 2 to 8 degrees Celsius, 15 to 25 degrees Celsius, and frozen — during the riskiest moment in a drug’s journey: the handoff between air and ground transport. That transfer point is where so-called temperature excursions are most likely, and where a single lapse can ruin a shipment. Industry-wide, cold-chain failures are estimated to cost up to $35 billion a year, and the World Health Organization blames them for up to half of all vaccine waste.

The timing tracks a clear shift in medicine. A new generation of treatments — cell and gene therapies, mRNA platforms and GLP-1 drugs like those driving the weight-loss boom — must stay within tight temperature limits from factory to patient. Demand for shipping temperature-sensitive biologics is projected to grow about 8.3% a year through 2033, reaching roughly $39.1 billion, according to Growth Market Reports.

“Biologics and personalized treatments are driving better, more targeted care for patients,” said John Bolla, president of UPS Healthcare.

The cold-chain push is the clearest sign yet of how UPS is remaking itself. Under chief executive Carol Tomé, the company has deliberately walked away from low-margin volume, cutting shipments for Amazon, long its largest customer, by more than half. By the end of June, UPS will have shed about 2 million Amazon packages a day and some $5 billion in revenue in under two years. To replace it, the company is chasing higher-paying business in healthcare, small business and B2B.

Healthcare is the centerpiece. UPS crossed $3 billion in quarterly healthcare revenue for the first time in early 2026 and has set a target of $20 billion in annual healthcare revenue. Tomé has singled out the rise of drugmakers shipping GLP-1 medicines straight to consumers, rather than to distributors, as a fresh opening.

The pivot has been painful elsewhere: UPS eliminated roughly 48,000 positions and closed 93 buildings in 2025, and plans to cut about 30,000 more jobs and shut additional sorting centers this year. First-quarter 2026 revenue slipped 1.4% to $21.2 billion, though adjusted earnings of $1.07 a share still beat Wall Street.

Analysts are watching whether the trade-off pays off. Barclays equity analyst Brandon Oglenski has noted that UPS expects roughly flat domestic operating income this year despite the steep volume decline — a far better outcome than past downturns, when profits fell much faster than volumes.

The new cross-docks, backed by UPS’s acquisitions of healthcare-logistics firms including Bomi Group, Frigo Trans and Andlauer Healthcare Group, are meant to lock in specialized, high-margin work that ordinary parcel rivals cannot easily copy.

The bet is straightforward: as everyday package delivery grows slower and more crowded, the medicines that need careful handling become the prize. UPS reports its next quarterly results in late July, when investors will look for proof that healthcare and other premium segments are filling the hole left by Amazon. Monday’s $48 million is small against the company’s roughly $89 billion in expected annual revenue, but it points squarely at where UPS believes its growth now lives.

JBizNews Desk
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.